Mercer Global Advisors Inc. ADV Has $527,000 Stock Position in Incyte Co. (NASDAQ:INCY)

Mercer Global Advisors Inc. ADV boosted its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 131.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 7,624 shares of the biopharmaceutical company's stock after acquiring an additional 4,329 shares during the period. Mercer Global Advisors Inc. ADV's holdings in Incyte were worth $527,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in shares of Incyte by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 4,040,086 shares of the biopharmaceutical company's stock worth $278,346,000 after purchasing an additional 103,910 shares during the period. AQR Capital Management LLC boosted its holdings in Incyte by 29.7% during the fourth quarter. AQR Capital Management LLC now owns 3,502,813 shares of the biopharmaceutical company's stock worth $241,519,000 after buying an additional 801,090 shares during the last quarter. LSV Asset Management grew its position in shares of Incyte by 18.6% during the 4th quarter. LSV Asset Management now owns 3,467,490 shares of the biopharmaceutical company's stock worth $239,500,000 after buying an additional 544,080 shares during the period. Norges Bank acquired a new position in shares of Incyte during the 4th quarter worth about $121,890,000. Finally, Northern Trust Corp increased its stake in shares of Incyte by 9.7% in the 4th quarter. Northern Trust Corp now owns 1,696,123 shares of the biopharmaceutical company's stock valued at $117,151,000 after acquiring an additional 150,672 shares during the last quarter. Institutional investors own 96.97% of the company's stock.

Incyte Stock Up 0.9%

INCY traded up $0.55 during trading hours on Friday, hitting $63.31. 1,330,051 shares of the company's stock were exchanged, compared to its average volume of 2,324,806. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. Incyte Co. has a 1-year low of $53.56 and a 1-year high of $83.95. The stock's 50-day moving average is $60.59 and its two-hundred day moving average is $68.54. The stock has a market cap of $12.25 billion, a price-to-earnings ratio of 234.49, a PEG ratio of 0.41 and a beta of 0.68.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.15. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The company had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $996.17 million. During the same quarter last year, the company earned $0.64 EPS. Incyte's revenue for the quarter was up 19.5% compared to the same quarter last year. Sell-side analysts predict that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INCY has been the topic of several recent analyst reports. Royal Bank of Canada lifted their price objective on shares of Incyte from $64.00 to $67.00 and gave the stock a "sector perform" rating in a research note on Wednesday, April 30th. JPMorgan Chase & Co. decreased their target price on Incyte from $70.00 to $68.00 and set a "neutral" rating for the company in a research note on Monday, April 21st. Wells Fargo & Company increased their price target on Incyte from $58.00 to $59.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Truist Financial cut their price objective on Incyte from $74.00 to $72.00 and set a "hold" rating on the stock in a report on Tuesday, March 18th. Finally, William Blair lowered Incyte from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $73.53.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the transaction, the executive vice president now owns 25,848 shares of the company's stock, valued at $1,809,101.52. The trade was a 2.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the sale, the executive vice president now owns 33,567 shares in the company, valued at $2,272,150.23. This represents a 37.11% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,475 shares of company stock worth $2,424,751 over the last ninety days. 17.80% of the stock is currently owned by corporate insiders.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.